A Review of Ferric Pyrophosphate Citrate (Triferic) Use in Hemodialysis Patients

PurposeThe objective of this short review is to evaluate the efficacy of ferric pyrophosphate citrate and to determine its place in therapy based on the current published literature.MethodsA literature search was conducted and pared down to yield 4 placebo controlled Phase II and III clinically relevant trials.FindingsFerric pyrophosphate citrate is a new intradialytic iron supplementation product that has been found to reduce the dose of erythropoiesis-stimulating agents and intravenous iron supplementation and to increase serum ferritin concentrations.ImplicationsThis agent may be administered to patients with stage 5 chronic kidney disease receiving hemodialysis as a new iron supplementation option to maintain hemoglobin, transferrin saturation, and ferritin concentrations.